Matthew J Schipper

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity
    Matthew J Schipper
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Biother Radiopharm 27:403-11. 2012
  2. pmc Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
    Peter L Roberson
    Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
    Eur J Nucl Med Mol Imaging 38:874-83. 2011
  3. pmc 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling
    Yuni K Dewaraja
    Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Nucl Med 51:1155-62. 2010
  4. pmc Stereotactic body radiation therapy for primary and metastatic liver tumors
    Erqi Liu
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    Transl Oncol 6:442-6. 2013
  5. pmc Regional variation in brain white matter diffusion index changes following chemoradiotherapy: a prospective study using tract-based spatial statistics
    Christopher H Chapman
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 8:e57768. 2013

Collaborators

Detail Information

Publications5

  1. pmc Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity
    Matthew J Schipper
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Biother Radiopharm 27:403-11. 2012
    ..For individualized treatment planning in radioimmunotherapy (RIT), correlations must be established between tracer-predicted and therapy-delivered absorbed doses. The focus of this work was to investigate this correlation for tumors...
  2. pmc Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
    Peter L Roberson
    Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
    Eur J Nucl Med Mol Imaging 38:874-83. 2011
    ..Biologically effective contributions, including the cold protein effect, are included in an equivalent biological effect model that was fit to patient data...
  3. pmc 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling
    Yuni K Dewaraja
    Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Nucl Med 51:1155-62. 2010
    ..Here, fully 3-dimensional (3D) dosimetry was performed coupling SPECT/CT at multiple time points with Monte Carlo-based voxel-by-voxel dosimetry to examine such correlations...
  4. pmc Stereotactic body radiation therapy for primary and metastatic liver tumors
    Erqi Liu
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    Transl Oncol 6:442-6. 2013
    ..Thus, we evaluated SBRT outcomes for primary and metastatic liver tumors, with the goal of identifying factors that may aid in optimization of therapy...
  5. pmc Regional variation in brain white matter diffusion index changes following chemoradiotherapy: a prospective study using tract-based spatial statistics
    Christopher H Chapman
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 8:e57768. 2013
    ..We used diffusion tensor imaging (DTI) to examine regional variation in white matter changes following chemoradiotherapy...